Ascletis Pharma (HKG:1672) will present the study results of its obesity products ASC30 tablets and injection, as well as the combination of ASC31 and ASC47 at ObesityWeek 2025 in Atlanta, Georgia, a Monday Hong Kong bourse filing said.
The poster presentations will take place at the international conference for obesity researchers and clinicians on Nov. 4.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.